# CG Oncology to Present at Upcoming Investor Conferences in September
Canonical URL: https://biopharmsignal.com/news/CGON/cg-oncology-to-present-at-upcoming-investor-conferences-in-september-67a2841f
Ticker: CGON
Company: CG Oncology, Inc.
Source: CG Oncology, Inc.
Published: 2026-09-02 12:00 EST
## Summary

CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive...

## Article Body
CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:

Cantor Fitzgerald Global Healthcare Conference Presentation Time: Wednesday, September 9, 2026 at 8:00am ET

Morgan Stanley Global Healthcare Conference Presentation Time: Monday, September 14, 2026 at 4:50pm ET

Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's website at www.cgoncology.com . The webcast replays will be available shortly after the conclusion of the live presentations and archived for approximately 90 days.

About CG Oncology CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts: Media Sarah Connors Vice President, Communications and Patient Advocacy, CG Oncology sarah.connors@cgoncology.com

Investor Relations Megan Knight Vice President, Investor Relations, CG Oncology megan.knight@cgoncology.com
## Recent Company News
- 2026-09-02 12:00 EST — [CG Oncology to Present at Upcoming Investor Conferences in September](https://biopharmsignal.com/news/CGON/cg-oncology-to-present-at-upcoming-investor-conferences-in-september-67a2841f) — Source: CG Oncology, Inc.
- 2026-08-06 12:15 EST — [CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/CGON/cg-oncology-reports-second-quarter-2026-financial-results-and-provides-business--af164da3) — Source: CG Oncology, Inc.
- 2026-07-27 22:45 EST — [CG Oncology Announces Publication of Pivotal Phase 3 BOND-003 Cohort C Study Results in The Lancet Oncology](https://biopharmsignal.com/news/CGON/cg-oncology-announces-publication-of-pivotal-phase-3-bond-003-cohort-c-study-res-236fb0f5) — Source: CG Oncology, Inc.
- 2026-05-28 20:05 EST — [CG Oncology to Present at Upcoming Investor Conferences in June](https://biopharmsignal.com/news/CGON/cg-oncology-to-present-at-upcoming-investor-conferences-in-june-3c0d37b0) — Source: CG Oncology, Inc.
- 2026-05-19 12:00 EST — [SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award](https://biopharmsignal.com/news/CGON/suo-ctc-and-cg-oncology-announce-award-recipients-of-the-second-annual-non-muscl-f95ea5a8) — Source: CG Oncology, Inc.
## Related News
- 2026-09-07 11:00 EST — ASND — [Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026](https://biopharmsignal.com/news/ASND/ascendis-to-share-its-latest-endocrinology-rare-disease-data-at-espe-2026-a501d9d2)
- 2026-09-07 07:53 EST — TEVA — [Teva Announces Launch of Offering of Senior Notes](https://biopharmsignal.com/news/TEVA/teva-announces-launch-of-offering-of-senior-notes-94143bde)
- 2026-09-06 05:00 EST — ROIV — [Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call](https://biopharmsignal.com/news/ROIV/roivant-to-present-topline-results-from-the-phase-2-phocus-study-of-mosliciguat--bf1ea553)
- 2026-09-04 20:30 EST — ORIC — [ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ORIC/oric-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635-c--e23953dd)
- 2026-09-04 20:05 EST — RPID — [Rapid Micro Biosystems to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/RPID/rapid-micro-biosystems-to-participate-in-upcoming-investor-conferences-91a8800f)